Clinical trials: Sudden Death
Cardiac Arrest, Out-Of-Hospital, Sudden Cardiac Arrest
Epinephrine Dose: Optimal Versus Standard Evaluation Trial
The objective of this randomized controlled trial is to evaluate whether a low cumulative dose of epinephrine ("low dose") is non-inferior to a standard cumulative dose of epinephrine ("standard dose") with respect to survival to…
- Conditions
- Cardiac Arrest, Out-Of-Hospital, Sudden Cardiac Arrest, Ventricular Fibrillation, Ventricular Tachycardia-Pulseless
- Trial name
- EpiDOSE (NCT03826524)
- Testing
- Epinephrine
- Where
- 9 sites in Canada
- Volunteers
- 1,250 people
- Sponsor
- Unity Health Toronto
Ischemic Heart Failure
LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry
The WEARIT-III registry enrolls subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator.
- Trial name
- WEARIT-III (NCT02700880)
- Testing
- LifeVest
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Zoll Medical Corporation
Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II)
Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children
Hypothesis: Children diagnosed with a lysosomal disease will exhibit developmental, adaptive, and behavioral strengths and difficulties depending upon 1) biomedical risk factors (i.e.
- Conditions
- Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), Mucopolysaccharidosis Type III (MPS III), Mucopolysaccharidosis Type VI (MPS VI)
- Trial name
- NCT01938014
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Rare Diseases, Fabry Disease
Evaluation of HEArt invoLvement in Patients With FABRY Disease
This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.
- Conditions
- Rare Diseases, Fabry Disease, Fabry Disease, Cardiac Variant, Hypertrophic Cardiomyopathy
- Trial name
- HEAL-FABRY (NCT03362164)
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Wuerzburg University Hospital
Sudden Cardiac Arrest
HeartStart HS1 Defibrillator* Event Registry
A Prospective study on the performance and safety of the HeartStart OnSite (Model M5066A) \& HeartStart Home (Model M5068A) Defibrillator device data.
- Trial name
- NCT04840797
- Testing
- HeartStart HS1
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Heartstream US LLC
Coronary Vasospasm, Cardiac Death
Coronary Spasm Presenting Aborted Sudden Cardiac Death, the Multicenter Registry
The purpose of this study is to evaluate the natural course of coronary spasm patients presenting aborted sudden cardiac death and analyze risk factors.
- Trial name
- NCT02298543
- Testing
- coronary spasm
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seung-Jung Park
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- HSCT+RIC (NCT01962415)
- Testing
- Hydroxyurea, Alemtuzumab, Fludarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Paul Szabolcs
Myocardial Infarction, Sudden Cardiac Death
Personalised Risk scOre For Implantation of Defibrillators in Patients With Preserved LVEF>35% and a High Risk for Sudden Cardiac Death
The objective of the study is to demonstrate that in post-MI patients with preserved LVEF>35% but high risk for SCD according to a personalised risk score, the implantation of an ICD (index group) is superior to optimal medical…
- Trial name
- NCT04540289
- Testing
- Optimal Medical Therapy (OMT), Implantable cardioverter-defibrillator (ICD)
- Sponsor
- Helios Health Institute GmbH
Diabetes Mellitus Type 2, End Stage Renal Disease
Surrogate Markers for Sudden Cardiac Death in Patients With Diabetes Mellitus and End Stage Renal Disease
Aim: Patients with type 2 diabetes mellitus (T2DM) and hemodialysis due to diabetic nephropathy exhibit a high risk for sudden cardiac death (SCD).
- Trial name
- NCT02001480
- Testing
- 12 lead Holter, CGM Continuous Glucose Monitoring
- Where
- 3 sites in Germany
- Volunteers
- 60 people
- Sponsor
- RWTH Aachen University
Epilepsy, Hypothalamus
Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy
Patients with drug-resistant epilepsy may have cardiac dysautonomia, with reduced heart rate variability and increased sympathetic tone.
- Conditions
- Epilepsy, Hypothalamus, Seizures- Cardiac Dysautonomia, SUDEP
- Trial name
- HYPOLEPSIE (NCT07888543)
- Testing
- MRI scan, electrocardiogram
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Cardiac Arrest (CA), Out-of-hospital Cardiac Arrest (OHCA)
Measurement of Airway Opening Index During Out-of-hospital Cardiac Arrest: The Lazarus AOI Trial.
Out-of-hospital cardiac arrest (OHCA) is a leading cause of death worldwide. Despite constantly improving resuscitation techniques, the chances of survival remain limited.
- Conditions
- Cardiac Arrest (CA), Out-of-hospital Cardiac Arrest (OHCA), Resuscitated Sudden Cardiac Death
- Trial name
- Lazarus-AOI (NCT07438938)
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- University Hospital, Ghent
Long QT Syndrome
Mutation-specific Therapy for the Long QT Syndrome
Novel therapy for the Long QT Syndrome based on the mechanism of action of the disease-causing mutations Long QT syndrome type 2 (LQT2) accounts for ~ 35% of all LQTS cases and is difficult to manage, as beta-blockers frequently…
- Trial name
- MAST2 (NCT04581408)
- Testing
- Lumacaftor / Ivacaftor, Orkambi® Oral Tablet
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Istituto Auxologico Italiano
Change in Serum Chloride Level
Change in Serum Chloride Level After Loading Dose of Sterofundin Solution Compared With Normal Saline Solution
Prospective, crossover, randomized trial to evaluate plasma compositions after loading dose of sterofundin solution given to healthy volunteer in the resuscitation manner compared with normal saline solution.
- Trial name
- NCT02950974
- Testing
- Sterofundin, NSS
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ramathibodi Hospital
Mucopolysaccharidosis Type II (MPS II)
CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system.
- Trial name
- NCT03566043
- Testing
- RGX-121
- Where
- 5 sites in United States, Brazil
- Volunteers
- 48 people
- Sponsor
- REGENXBIO Inc.
ICD Malfunction, Sudden Cardiac Death
S-ICD Electrode Registry
The subcutaneous implantable cardioverter defibrillator (S-ICD) is established in the prevention of sudden cardiac death, but recently a defect of the electrode's Sense-B component was reported in some patients.
- Trial name
- NCT05713708
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Universitätsklinikum Köln
Mucopolysaccharidosis II
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II
Phase 1, open-label, sequential ascending dose-escalation study. Designed to evaluate the safety and efficacy of a single IV infusion of investigational gene therapy HMI-203.
- Trial name
- NCT05238324
- Testing
- Genetic HMI-203
- Where
- 6 sites in United States, Canada
- Sponsor
- Homology Medicines, Inc
Congenital Heart Disease, Coronary Artery Anomaly
European Prospective Registry on Anomalous Aortic Origin of the Coronary Arteries
Anomalous aortic origin of a coronary artery (AAOCA) is a group of rare congenital heart defects with various clinical presentations.
- Conditions
- Congenital Heart Disease, Coronary Artery Anomaly, Sudden Cardiac Death, Surgical Procedure, Unspecified
- Trial name
- EUROAAOCA (NCT06089902)
- Testing
- unroofing or other surgery if needed
- Where
- 2 sites in Italy, Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Padova
Acute STEMI, Severe Left Ventricular Systolic Dysfunction (Disorder)
Use of Cardiac MRI in Early Stages of STEMI to Predict Left Ventricular Function Recovery and ICD Implantation
Patients presenting with STEMI and late revascularization can suffer from severe left ventricular dysfunction. Midterm and longterm mortality can be determined by the risk of fatal ventricular arrythmias.
- Trial name
- STEMI-MR (NCT03743935)
- Testing
- Gadolinium-enhanced cardiac MRI
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Montpellier
Hypertrophic Cardiomyopathy (HCM)
Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy
This study will review medical information collected on children and adolescents with hypertrophic cardiomyopathy (HCM) to try to identify risk factors for arrhythmias (abnormal heart rhythms) in these patients and better guide…
- Trial name
- NCT00753233
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Ventricular Arrhythmias and Cardiac Arrest
Epicardial Ablation in Brugada Syndrome to Prevent Sudden Death
A total of 150 patients will be randomized to perform catheter ablation or not in a 2:1 fashion in selected patients with Brugada-related symptoms (Ablation+ICD arm 105 patients vs ICD only 45 patients).
- Trial name
- NCT03294278
- Testing
- ablation plus ICD
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Policlinico S. Donato